What it costs the NHS to care for lung cancer that has spread to the brain
Original title: Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a cost study built with a computer model, not a new treatment tested in people.
The short version
This study looked at the cost of care, not at how well the drugs work.
What was studied. Researchers built a cost model for the UK's NHS. It looked at people with advanced ALK positive non small cell lung cancer, some with cancer that had spread to the brain and some without. All were on a first drug from a group called ALK tyrosine kinase inhibitors: lorlatinib, crizotinib, alectinib, or brigatinib.
What they found. In the first year of treatment, the model put the cost of caring for a patient with cancer spread to the brain at 14,870 pounds. For a patient without brain spread, it was 4,133 pounds. The model also found that lorlatinib saved the NHS more money as time went on. The savings were larger for people who had no brain spread when they started the drug.
What this means, and what it doesn't
What it could mean: Cancer that spreads to the brain is expensive to manage. A drug that helps stop that spread may lower those costs. Cost is one of the things a health system weighs when it decides which drug to offer.
What it doesn't mean: This does not mean lorlatinib will help you live longer. The study measured money, not how patients felt or how long they lived. The numbers came from a computer model built on trial data, not from tracking real bills. It is not a cure, and it does not say which drug is right for any one person. It also applies to the NHS in the UK, so costs elsewhere may differ. This is about lung cancer that spreads to the brain, not a tumor that starts in the brain.
Source: PubMed, July 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.